Weekly Analysts’ Ratings Updates for Abbott Laboratories (ABT)

Abbott Laboratories (NYSE: ABT) recently received a number of ratings updates from brokerages and research firms:

  • 1/30/2018 – Abbott Laboratories had its price target raised by analysts at Argus from $66.00 to $80.00. They now have a “buy” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/30/2018 – Abbott Laboratories had its price target raised by analysts at Citigroup Inc from $59.00 to $64.00. They now have a “neutral” rating on the stock.
  • 1/25/2018 – Abbott Laboratories had its price target raised by analysts at Barclays PLC from $66.00 to $70.00. They now have an “overweight” rating on the stock.
  • 1/25/2018 – Abbott Laboratories had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $72.00 price target on the stock.
  • 1/25/2018 – Abbott Laboratories had its “buy” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $67.00 price target on the stock.
  • 1/25/2018 – Abbott Laboratories had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $68.00 price target on the stock, up previously from $60.00.
  • 1/25/2018 – Abbott Laboratories had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $69.00. They now have an “overweight” rating on the stock.
  • 1/25/2018 – Abbott Laboratories had its price target raised by analysts at Morgan Stanley from $67.00 to $70.00. They now have an “overweight” rating on the stock.
  • 1/25/2018 – Abbott Laboratories had its price target raised by analysts at Wells Fargo & Co from $66.00 to $70.00. They now have an “outperform” rating on the stock.
  • 1/25/2018 – Abbott Laboratories had its price target raised by analysts at BMO Capital Markets from $65.00 to $70.00. They now have an “outperform” rating on the stock.
  • 1/25/2018 – Abbott Laboratories had its price target raised by analysts at Stifel Nicolaus from $63.00 to $71.00. They now have a “buy” rating on the stock.
  • 1/25/2018 – Abbott Laboratories was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.
  • 1/24/2018 – Abbott Laboratories had its price target raised by analysts at Bank of America Corp from $60.00 to $70.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/22/2018 – Abbott Laboratories was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/19/2018 – Abbott Laboratories had its “market perform” rating reaffirmed by analysts at Leerink Swann.
  • 1/9/2018 – Abbott Laboratories had its “buy” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $65.00 price target on the stock.
  • 1/8/2018 – Abbott Laboratories had its “buy” rating reaffirmed by analysts at Barclays PLC. They now have a $66.00 price target on the stock.
  • 1/3/2018 – Abbott Laboratories was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Post a promising third-quarter performance by Abbott, we are optimistic about the strong and consistent EPD and Medical Devices performance. However, the ongoing sluggish trend in the Nutrition business is a downside. However, the company continues to benefit from the recently completed St. Jude Medical buyout. Meanwhile, Alere acquisition close is an upside too. Through 2017, Abbott is effectively focusing on core therapeutic areas. Recently, its FreeStyle Libre Flash received the FDA approval. Also, it has received approval for MR-conditional labeling for Ellipse ICD. Also, emerging market performance remains promising on several new strategic developments. Hence, in the past three months, Abbott is trading above the broader industry. On the flip side, sluggish pediatric nutrition business in some global markets continues to dent growth. Also the economic problems in Venezuela are expected to remain unresolved.”
  • 1/3/2018 – Abbott Laboratories is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $64.00 price target on the stock.
  • 1/2/2018 – Abbott Laboratories was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $64.00 price target on the stock. According to Zacks, “Post a promising third-quarter performance by Abbott, we are optimistic about the strong and consistent EPD and Medical Devices performance. However, the ongoing sluggish trend in the Nutrition business is a downside. However, the company continues to benefit from the recently completed St. Jude Medical buyout. Meanwhile, Alere acquisition close is an upside too. Through 2017, Abbott is effectively focusing on core therapeutic areas. Recently, its FreeStyle Libre Flash received the FDA approval. Also, it has received approval for MR-conditional labeling for Ellipse ICD. Also, emerging market performance remains promising on several new strategic developments. Hence, in the past three months, Abbott is trading above the broader industry. On the flip side, sluggish pediatric nutrition business in some global markets continues to dent growth. Also the economic problems in Venezuela are expected to remain unresolved.”
  • 1/2/2018 – Abbott Laboratories was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $60.00 price target on the stock.
  • 1/2/2018 – Abbott Laboratories was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $67.00 price target on the stock.
  • 12/19/2017 – Abbott Laboratories was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Post a promising third-quarter performance by Abbott, we are optimistic about the strong and consistent EPD and Medical Devices performance. However, the ongoing sluggish trend in the Nutrition business is a downside. However, the company continues to benefit from the recently completed St. Jude Medical buyout. Meanwhile, Alere acquisition close is an upside too. Through 2017, Abbott is effectively focusing on core therapeutic areas. Recently, its FreeStyle Libre Flash received the FDA approval. Also, it has received approval for MR-conditional labeling for Ellipse ICD. Also, emerging market performance remains promising on several new strategic developments. Hence, in the past three months, Abbott is trading above the broader industry. On the flip side, sluggish pediatric nutrition business in some global markets continues to dent growth. Also the economic problems in Venezuela are expected to remain unresolved.”

Abbott Laboratories (ABT) traded down $0.01 during trading hours on Monday, hitting $57.16. The stock had a trading volume of 1,781,622 shares, compared to its average volume of 7,773,765. Abbott Laboratories has a fifty-two week low of $42.31 and a fifty-two week high of $64.60. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. The company has a market cap of $99,510.00, a PE ratio of 285.80, a PEG ratio of 1.72 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The business had revenue of $7.59 billion for the quarter, compared to analysts’ expectations of $7.38 billion. During the same quarter in the previous year, the business posted $0.65 EPS. Abbott Laboratories’s revenue for the quarter was up 42.3% on a year-over-year basis. equities analysts anticipate that Abbott Laboratories will post 2.86 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 1.96%. The ex-dividend date is Thursday, January 11th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.27. Abbott Laboratories’s payout ratio is 560.00%.

In other Abbott Laboratories news, insider Alejandro D. Wellisch sold 2,153 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total value of $120,266.58. Following the sale, the insider now owns 10,256 shares in the company, valued at approximately $572,900.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brian J. Blaser sold 23,866 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $55.55, for a total value of $1,325,756.30. Following the completion of the sale, the insider now owns 146,387 shares in the company, valued at approximately $8,131,797.85. The disclosure for this sale can be found here. Insiders have sold a total of 445,615 shares of company stock worth $24,666,341 in the last quarter. 0.76% of the stock is currently owned by company insiders.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply